Samuel Hamilton
Clinical Researcher
Papers
Trials
Key Impact
Notable for leading and co-authoring multiple controlled clinical trials and pooled analyses that advanced MDMA-assisted psychotherapy for PTSD and anxiety-related disorders, informing phase 3 development and long-term outcome assessment.
Background & Research
Samuel Hamilton is a clinical researcher specialising in the clinical development of MDMA-assisted psychotherapies for trauma- and illness-related psychiatric conditions. He has been centrally involved in a programme of randomised, double-blind, dose-response and phase 2 clinical trials examining MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) in high-risk cohorts (including military veterans, firefighters and police officers), as well as pilot work on MDMA-assisted therapy for anxiety and psychological distress associated with life‑threatening illness. His work spans trial design, operational delivery of multi-site studies, and analysis of acute clinical outcomes.
Hamilton has contributed to pooled longitudinal analyses and long-term follow-up studies that assess durability of therapeutic effects and safety signals following MDMA-assisted psychotherapy, and has co-authored the rationale and design papers that underpinned phase 3 development. His research emphasis includes methodological rigour in randomised controlled trials, dose‑response characterisation, measurement of suicidality and depressive comorbidity in PTSD populations, and the translation of early-phase findings into confirmatory late-phase trials and clinical practice considerations.